Bio-Rad feels unloved by the investment community
This article was originally published in Clinica
Executive Summary
We are somewhat undervalued in the financial market," Bio-Rad's vice-president, Norman Schwartz, told a recent UBS Warburg Global Life Sciences conference in New York. Explaining how the $700 million turnover company derives its income for life sciences laboratory analysis and clinical diagnostics, he characterised Bio-Rad as a company "providing tools for discovery and for diagnostic testing".
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.